Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Circulating tumor DNA is a prognostic biomarker in metastatic melanoma patients treated with chemoimmunotherapy and BRAF inhibitor.
Mattila KE, Mäkelä S, Kytölä S, Andersson E, Vihinen P, Ramadan S, Skyttä T, Tiainen L, Vuoristo MS, Tyynelä-Korhonen K, Koivunen J, Kohtamäki L, Aittomäki K, Hernberg M. Mattila KE, et al. Among authors: tiainen l. Acta Oncol. 2022 Oct;61(10):1263-1267. doi: 10.1080/0284186X.2022.2137693. Epub 2022 Oct 28. Acta Oncol. 2022. PMID: 36307938 Clinical Trial.
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B. Jansen YJL, et al. Among authors: tiainen l. Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110. Ann Oncol. 2019. PMID: 30923820 Free article.
High baseline Tie1 level predicts poor survival in metastatic breast cancer.
Tiainen L, Korhonen EA, Leppänen VM, Luukkaala T, Hämäläinen M, Tanner M, Lahdenperä O, Vihinen P, Jukkola A, Karihtala P, Aho S, Moilanen E, Alitalo K, Kellokumpu-Lehtinen PL. Tiainen L, et al. BMC Cancer. 2019 Jul 24;19(1):732. doi: 10.1186/s12885-019-5959-8. BMC Cancer. 2019. PMID: 31340773 Free PMC article. Clinical Trial.
Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma.
Mattila KE, Vihinen P, Ramadan S, Skyttä T, Tiainen L, Vuoristo MS, Tyynelä-Korhonen K, Koivunen J, Kohtamäki L, Mäkelä S, Hernberg M. Mattila KE, et al. Among authors: tiainen l. Acta Oncol. 2020 Mar;59(3):310-314. doi: 10.1080/0284186X.2019.1670862. Epub 2019 Sep 28. Acta Oncol. 2020. PMID: 31564175 No abstract available.
Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy.
Vihinen H, Jokinen A, Laajala TD, Wahid N, Peltola L, Kettunen T, Rönkä A, Tiainen L, Skyttä T, Kohtamäki L, Tulokas S, Karhapää H, Hernberg M, Silvoniemi M, Mattila KE. Vihinen H, et al. Among authors: tiainen l. Clin Lung Cancer. 2023 Jun;24(4):295-304. doi: 10.1016/j.cllc.2023.01.004. Epub 2023 Jan 24. Clin Lung Cancer. 2023. PMID: 36774235 Free article.
Radiological and pathological assessment of response to neoadjuvant CDK4/6 inhibitor and endocrine treatments in a real-life setting-initial results.
Moisander M, Salminen A, Jukkola A, Sassi A, Tervo M, Mäenpää N, Tiainen L, Rinta-Kiikka I, Tolonen T, Arponen O. Moisander M, et al. Among authors: tiainen l. Acta Radiol Open. 2021 Aug 17;10(8):20584601211030660. doi: 10.1177/20584601211030660. eCollection 2021 Aug. Acta Radiol Open. 2021. PMID: 34422318 Free PMC article.
17 results